Abstracts tagged "pregnancy"

Abstract Number: 2292 • ACR Convergence 2023
Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?
Dina Zucchi¹, Giancarlo Cascarano², Antonio Collesei³, Elena Elefante², Francesca Monacci⁴, Chiara Ietto⁴, Linda Carli², Sabrina Gori², Valentina Gelsi⁴, Chiara Tani² and Marta Mosca², ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy, ⁴Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis…
Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Antía García-Fernández¹, Fernando Rengifo-García¹, Raquel Senosiain-Echarte¹, Miguel álvaro-Navidad¹, Miguel A Gonzalez-Gay² and Juan A Martínez-López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Anna Molto¹, aya ajrouche², Diep Tran², Nathalie Costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁵, Bruno Fautrel⁷ and Florence Tubach², ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴APHP, Paris, France, ⁵Paris-Cité University, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Sorbonne Université APHP, Paris, France
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…
Abstract Number: 1355 • ACR Convergence 2023
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Rebecca O'Farrell¹, Sinead Maguire², Louise Moore³, Kieran Murray⁴, Áine Gorman⁵, Elisabeth Ball⁶, Claire Riddell⁶, Madeline O'Neill⁷, Natasha Jordan⁸, Barry O'Shea⁹, Douglas Veale¹⁰, Suzanne Donnelly¹¹, Grainne Murphy¹² and Gillian Fitzgerald¹³, ¹Department of Rheumatology, Galway, Dublin, Ireland, ²Toronto Western Hospital, Toronto, ON, Canada, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Harold's Cross,, Ireland, ⁴University Hospital Limerick, Limerick, Ireland, ⁵Royal United Hospital, Bath, United Kingdom, ⁶Belfast Health and Social Care Trust, Belfast, United Kingdom, ⁷Our Lady's Hospice, Harold's Cross, Dublin, Ireland, ⁸Addenbrooke's Hospital, Cambridge, United Kingdom, ⁹St James's Hospital, Dublin, Ireland, ¹⁰St.Vincent's University Hosp, Dublin, Ireland, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland, ¹²Cork University Hospital, Cork, Ireland, ¹³University Hospital Galway, Galway, Ireland
Background/Purpose: Rheumatic disease frequently affects women of childbearing age. Women with pre-existing rheumatic disease who are planning a pregnancy or develop these conditions during pregnancy…
Abstract Number: 2425 • ACR Convergence 2023
Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
Amadeia Rector¹, Julia Simard², Gary Shaw³ and Audra Horomanski⁴, ¹Stanford University, San Francisco, CA, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent management and therapeutic advances have improved life expectancy and reproductive…
Abstract Number: 0103 • ACR Convergence 2023
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
Tiphaine Goulenok¹, Clothilde Gros¹, Arthur Mageau², Tiphaine Barral¹, Pascale Roland Nicaise¹, Marie Helene Saint Frison¹, Margot Bucau¹, Valerie Vivier¹, Valentine Marie Ferre², Agnes Bourgeois Moine¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…
Abstract Number: 0478 • ACR Convergence 2023
The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children
Maria Grazia Lazzaroni¹, Eleonora Pedretti¹, Liala Moschetti¹, Marzia Bendoni², Lucrezia Visconti², Anna Molinaro², Cecilia Nalli³, Franco Franceschini³, Paolo Airò¹, Jessica Galli², Elisa Fazzi², Angela Tincani⁴ and Laura Andreoli⁵, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ²Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ⁵University of Brescia, Brescia, Italy
Background/Purpose: The long-term neuropsychiatric (NP) outcome of children born to mothers affected by autoimmune diseases (AIDs) represents a controversial topic, with few studies1-3 reporting a…
Abstract Number: 1357 • ACR Convergence 2023
Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review
Erinn Coe¹, Emily Petrinec¹ and Omer Pamuk², ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to…
Abstract Number: 2481 • ACR Convergence 2023
Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Matthew Wright¹, Mette Smed², Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Nicholas Jewell⁶, Vibeke Zoffmann² and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, ³Fred Hutchinson Cancer Center, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
Abstract Number: 0104 • ACR Convergence 2023
Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study
Yin Long¹, Jiuliang zhao², Mengtao Li², Xinping Tian² and xiaofeng Zeng³, ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
Abstract Number: 0479 • ACR Convergence 2023
Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry
Catherine Sims¹, Christine Yeung², Heather Tam³, Joyce Kullman⁴, Amanda Eudy⁵, Renee Borchin⁶, Cristina Burroughs⁶, Megan Clowse⁷ and Peter Merkel², ¹Duke University School of Medicine, Durham, NC, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Patient Powered Research Network, Stanford, CA, ⁴Vasculitis Foundation, Kansas City, MO, ⁵Duke University, Raleigh, NC, ⁶University of South Florida, Tampa, FL, ⁷Duke University, Chapel Hill, NC
Background/Purpose: There are limited data on the reproductive health and experiences of women with vasculitis. This study engaged women with vasculitis to understand their perspectives…
Abstract Number: 1360 • ACR Convergence 2023
Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort
Yvette Meissner¹, Bernhard Eickhoff¹, Cornelia Glaser², Joerg Henes³, Jutta Richter⁴, Susanna Spaethling-Mestekemper⁵, Christof Specker⁶, Rebecca Fischer-Betz⁴ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology University Medical Center Freiburg, Freiburg, Germany, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, ⁵Rheumapraxis Muenchen, Muenchen, Germany, ⁶Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Pregnancies in women with chronic diseases are often accompanied by concerns about potential complications [1]. This analysis explored medication-related concerns among women with inflammatory…
Abstract Number: 0110 • ACR Convergence 2023
Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss
Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…

« Previous Page
1
…
3
4
5
6
7
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].